Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHNT.L Regulatory News (HNT)

  • There is currently no data for HNT

Interim Management Statement

18 Nov 2011 07:00

RNS Number : 3283S
Huntsworth PLC
18 November 2011
 



18 November 2011

Huntsworth plc

("Huntsworth" or "the Group")

 

Interim Management Statement

 

Highlights

·; 7% like-for-like revenue growth in third quarter

·; Seven-figure wins for 2012 for Huntsworth Health, Grayling and Red

·; Macro-economic uncertainty leads to client cancellations of £4m of year-end projects

Overview

Huntsworth plc, the international public relations and healthcare communications group, today publishes its Interim Management Statement for the period since 30 June 2011.

Like-for-like revenues grew by 7% in the third quarter year on year. Citigate reported 15.5% growth, Grayling 5.2%, Huntsworth Health 3.7% and Red 15.6%.

Grayling, Huntsworth Health and Red recorded significant international and multi-office business wins in the third quarter. These seven-figure wins will be fully operational during the first quarter of 2012 and together with our existing annual retainer clients will provide a strong base for Huntsworth going forward.

Sally Withey, Chief Operating Officer of Huntsworth, said:

"The Group strategy is to win two and three year global and multi-office contracts. The pipeline for these larger mandates is good and following our brand rationalisation, our success in winning them has considerably improved in the third quarter. These new global and multi-office wins which we announce today will be on stream in early 2012."

The balance sheet remains robust and we continue to operate within our banking covenants.

Current trading

"We have recently experienced the cancellation of over £4m of scheduled year-end projects due to global economic uncertainty. The timing of these cutbacks coming so late in the year will not enable us to reduce costs accordingly. We therefore expect to fall short of management profit expectations by £4m," said Sally Withey.

"In the UK and Europe - geographies which together account for 62% of Huntsworth revenues - these cutbacks are in fast moving consumer goods, consumer durables, environmental and CSR programmes and, in the USA, nervousness in the pharmaceutical industry is slowing spending decisions and delaying new business starts.

"On the assumption that these client cutbacks are further signs of a lasting economic downturn in our primary European markets, we have taken the decision to reduce our cost base to ensure that, within six weeks, at the start of 2012, we will have returned the Group to its historic operating margins."

Contacts:

Huntsworth plc +44 (0)207 224 8778

Peter Chadlington, Chief Executive

Sally Withey, Chief Operating Officer

Colin Adams, Finance Director

 

Citigate Dewe Rogerson +44 (0)207 638 9571

Simon Rigby

Angharad Couch

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSDKODDOBDDBDD
Date   Source Headline
6th Mar 20195:09 pmRNSHolding(s) in Company
6th Mar 20197:00 amRNSDirectorate Change
5th Mar 20197:00 amRNSPreliminary Results for year end 31 December 2018
4th Feb 20195:15 pmRNSHolding(s) in Company
28th Jan 20195:45 pmRNSHolding(s) in Company
21st Jan 20197:00 amRNSNotice of Results
11th Jan 20194:01 pmRNSHolding(s) in Company
7th Jan 20195:53 pmRNSStandard form for notification of major holdings
7th Jan 20195:14 pmRNSStandard form for notification of major holdings
7th Jan 20193:08 pmRNSStandard form for notification of major holdings
19th Dec 201810:00 amRNSDirectorate Change and Appointment of Chairman
17th Dec 201812:07 pmRNSSecond Price Monitoring Extn
17th Dec 201812:02 pmRNSPrice Monitoring Extension
13th Dec 20184:27 pmRNSHoldings in Company
12th Dec 20187:00 amRNSTrading Update
4th Dec 20186:04 pmRNSHolding(s) in Company
3rd Dec 20187:00 amRNSTotal Voting Rights and Capital
12th Nov 20181:25 pmRNSDirector/PDMR Shareholding
8th Nov 20182:23 pmRNSDirector Declaration
6th Nov 20183:23 pmRNSDirector/PDMR Shareholding
5th Nov 20187:00 amRNSAdditional Listing
1st Nov 20187:00 amRNSNotification of Total Voting Rights and Capital
29th Oct 20184:35 pmRNSPrice Monitoring Extension
10th Oct 20184:56 pmRNSHolding in Company
9th Oct 20185:15 pmRNSDirector/PDMR Shareholding
8th Oct 20184:56 pmRNSTransfer of Treasury Shares
4th Oct 20184:31 pmRNSNotification of Major Holdings
4th Oct 20183:31 pmRNSScrip Dividend Alternative
4th Oct 20187:00 amRNSCompletion of Acquisition
3rd Oct 20184:57 pmRNSNotification of Major Holdings
3rd Oct 20184:41 pmRNSStandard form for notification of major holdings
3rd Oct 201810:43 amRNSNotification of Major Holdings
1st Oct 20185:22 pmRNSNotification of Major Holdings
28th Sep 201810:00 amRNSStandard form for notification of major holdings
28th Sep 20187:00 amRNSResults of placing
27th Sep 20184:56 pmRNSProposed acquisition of Navience Healthcare
26th Sep 20183:13 pmRNSStandard form for notification of major holdings
10th Aug 20185:01 pmRNSHolding in Company
10th Aug 20184:59 pmRNSHolding in Company
1st Aug 20187:00 amRNSTotal Voting Rights and Capital
24th Jul 20187:00 amRNSInterim results for the six months to 30 June 2018
17th Jul 20187:00 amRNSAcquisition of Giant Creative Strategy LLC
13th Jul 20184:11 pmRNSHolding in Company
12th Jul 201812:38 pmRNSHolding in Company
11th Jul 20183:00 pmRNSHolding in Company
5th Jul 20181:37 pmRNSHolding in Company
5th Jul 201810:07 amRNSDirector/PDMR Shareholding
4th Jul 20187:00 amRNSAdditional Listing
3rd Jul 201810:05 amRNSHolding in Company
3rd Jul 201810:04 amRNSHolding in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.